Enlivex Announces Positive DSMB Recommendation and IMOH Clearance to Continue Phase I/II Trial of Allocetra in Patients with Advanced Solid Tumors

On Janaury 25, 2023 Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a clinical-stage macrophage reprogramming immunotherapy company, reported that an independent Data and Safety Monitoring Board (DSMB) has completed its prespecified data review for the first cohort of patients in the Company’s ongoing Phase I/II cell therapy clinical trial of AllocetraTM in patients with advanced-stage solid tumors (clinicaltrials.gov Identifier: NCT05581719) (Filing, 6-K, Enlivex Therapeutics, JAN 25, 2023, View Source [SID1234626532]). The Israeli Ministry of Health (IMOH) also reviewed the data and provided regulatory clearance to continue the study and open the study’s additional cohorts.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The DSMB based its review on available safety data for the three enrolled patients in the first cohort in which three, once-weekly, low starting doses of AllocetraTM were administered as monotherapy. The dose-limiting toxicity period extended for one week following the last administration with an overall follow-up of 21 days. The primary purpose of the dosing regimen for the first cohort was to establish a safety profile that may enable an increase in the AllocetraTM dosing level administered to additional patients in the study and potentially associate dose levels with indications of effect.

There were no mortalities nor DSMB-identified safety signals in the first cohort, and the DSMB recommended that the study continue as designed. Following the DSMB recommendation, the IMOH reviewed the safety data for the first cohort and provided a regulatory clearance to initiate the recruitment of patients into the two following cohorts in the study, both of which will be administered higher AllocetraTM doses – one as monotherapy and the other in combination with anti-PD1 therapy.

Oren Hershkovitz, Ph.D., CEO of Enlivex, commented, "We are pleased with the safety profile of AllocetraTM as demonstrated in the first three patients in this trial. We look forward to initiating the next two cohorts in which higher doses of AllocetraTM will be administered in patients, allowing Enlivex to obtain additional safety data as well as a potential indication of effect."

ABOUT THE PHASE I/II TRIAL

The Phase I/II trial is a multicenter, open-label, dose escalation trial that is expected to enroll up to 48 patients with advanced solid tumors across two trial stages. Stage 1 of the trial will examine escalating doses of Allocetra monotherapy administered intravenously (IV) or intraperitoneally (IP) once a week for three consecutive weeks. Stage 2 will evaluate escalating doses of Allocetra administered IV or IP and combined with anti-PD1 therapy. Patients in Stage 2 will receive three injections of Allocetra concomitantly with the studied anti-PD1 agent. The primary objective of the study is to evaluate safety and tolerability throughout the treatment period and through one week after the last administration of Allocetra. Key secondary endpoints include efficacy assessments, such as best overall response rate, progression-free survival, and overall survival. Changes in immune cell/cytokine profiling in peritoneal fluid will also be assessed as an exploratory endpoint. The study population encompasses adult patients with advanced, unresectable or metastatic solid tumors that have relapsed or have been refractory to available approved therapies, or patients who are not eligible for, or have declined additional standard-of-care systemic therapy.

ABOUT ALLOCETRA

Allocetra is being developed as a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, Allocetra has the potential to provide a novel immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as "unmet medical needs", as a stand-alone therapy or in combination with leading therapeutic agents.

Allogene Therapeutics Publishes Preclinical Data in Clinical Cancer Research Supporting DLL3 as a Potential AlloCAR T™ Target for Small Cell Lung Cancer

On January 25, 2023 Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer, reported the publication of a preclinical study demonstrating delta-like ligand 3 (DLL3) is a promising tumor target for AlloCAR T in small cell lung cancer (SCLC) (Press release, Allogene, JAN 25, 2023, View Source [SID1234626530]). The findings were published in Clinical Cancer Research, a journal of the American Association for Cancer Research (AACR) (Free AACR Whitepaper).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

SCLC is an aggressive disease with limited treatment options. Approximately 30,000 patients in the United States are affected each year with this disease which has a 5-year overall survival rate of approximately 7%.1 DLL3, with high expression on tumors and limited expression in normal tissue, is a promising target for SCLC and potentially other solid tumors.

"As a leader in allogeneic CAR T research and development, we are committed to exploring the potential of this therapeutic modality across a broad range of indications, including in solid tumors where there is significant need," said Barbra Sasu, Ph.D., Chief Scientific Officer at Allogene.

This study describes the selection of ALLO-213 as an allogeneic CAR T development candidate targeting DLL3 from a large number of single chain variable fragment (scFv)-based anti-DLL3 CAR candidates. The selection of ALLO-213 was based on potency and specificity against SCLC cell lines in vitro and in vivo, including cell lines with very low antigen density to establish sensitivity. The results from the pre-clinical study showed:

No DLL3 on target toxicity was observed in preclinical models supporting a potentially attractive safety profile
Clinical DLL3 CAR candidates controlled DLL3+ tumor growth in mice without normal tissue toxicity

ABBOTT REPORTS FOURTH-QUARTER AND FULL-YEAR 2022 RESULTS; ISSUES 2023 FINANCIAL OUTLOOK

On January 25, 2023 Abbott (NYSE: ABT) reported financial results for the fourth quarter ended Dec. 31, 2022 (Press release, Abbott, JAN 25, 2023, View Source [SID1234626529]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Fourth-quarter sales of $10.1 billion, which were negatively impacted by an expected year-over-year decline in COVID-19 testing-related sales, decreased 12.0 percent on a reported basis and 6.1 percent on an organic basis, which excludes the impact of foreign exchange.
Excluding COVID-19 testing-related sales1, fourth-quarter sales decreased 1.4 percent on a reported basis and increased 5.4 percent on an organic basis.
Excluding COVID-19 testing-related sales2 and U.S. infant formula sales that were impacted by manufacturing disruptions3, full-year 2022 sales increased 1.9 percent on a reported basis and 7.4 percent on an organic basis.
GAAP diluted EPS was $0.59 in the fourth quarter. Excluding specified items, adjusted diluted EPS was $1.03.
Abbott issues full-year 2023 guidance for diluted EPS from continuing operations on a GAAP basis of $3.05 to $3.25 and full-year adjusted EPS from continuing operations of $4.30 to $4.50.
Abbott projects full-year 2023 organic sales growth, excluding COVID-19 testing-related sales, of high-single digits4 and COVID-19 testing-related sales of around $2.0 billion.
In October, Abbott’s market-leading FreeStyle Libre continuous glucose monitoring system was named the "Best Medical Technology" of the last 50 years by the Galien Foundation.
In December, Abbott announced U.S. Food and Drug Administration (FDA) approval of its Eterna spinal cord stimulation system — the smallest implantable, rechargeable system currently available for the treatment of chronic pain.5
In January, Abbott announced U.S. FDA approval of its minimally invasive Navitor transcatheter aortic valve implantation (TAVI) system for people with severe aortic stenosis who are at high risk for surgery.
"We significantly exceeded the EPS guidance we provided at the beginning of last year despite challenging global business conditions," said Robert B. Ford, chairman and chief executive officer, Abbott. "Our R&D pipeline continues to be highly productive with several recent and upcoming new product launches that position us well going forward."

FOURTH-QUARTER BUSINESS OVERVIEW

Note: Management believes that measuring sales growth rates on an organic basis is an appropriate way for investors to best understand the underlying performance of the business. Organic sales growth excludes the impact of foreign exchange. In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates. Management further believes that measuring sales growth rates on an organic basis excluding COVID-19 tests is an appropriate way for investors to best understand the underlying performance of the business in the fourth quarter ended Dec. 31, 2022 as well as in 2023 as the COVID-19 pandemic shifts to an endemic state, resulting in significantly lower expected demand for COVID-19 tests.

Total Company

($ in millions)

% Change vs. 4Q21

Sales 4Q22

Reported

Organic

U.S.

Int’l

Total

U.S.

Int’l

Total

U.S.

Int’l

Total

Total 6

4,219

5,872

10,091

(13.1)

(11.2)

(12.0)

(13.1)

(0.9)

(6.1)

Nutrition

795

1,022

1,817

(14.4)

(8.3)

(11.1)

(14.4)

1.4

(5.7)

Diagnostics

1,695

1,610

3,305

(29.0)

(22.8)

(26.1)

(29.0)

(12.5)

(21.3)

Established Pharmaceuticals

1,216

1,216

n/a

1.0

1.0

n/a

7.9

7.9

Medical Devices

1,726

2,024

3,750

12.2

(8.4)

12.2

4.1

7.4

% Change vs. 12M21

Sales 12M22

Reported

Organic

U.S.

Int’l

Total

U.S.

Int’l

Total

U.S.

Int’l

Total

Total 6

18,142

25,511

43,653

9.0

(3.5)

1.3

9.0

4.7

6.4

Nutrition

2,919

4,540

7,459

(17.9)

(4.2)

(10.1)

(17.9)

2.5

(6.2)

Diagnostics

8,646

7,938

16,584

21.3

(6.8)

6.0

21.3

1.3

10.4

Established Pharmaceuticals

4,912

4,912

n/a

4.1

4.1

n/a

10.6

10.6

Medical Devices

6,566

8,121

14,687

10.9

(3.8)

2.2

10.9

6.2

8.1

n/a = Not Applicable.

Worldwide COVID-19 testing-related sales were $1.069 billion in the fourth quarter of 2022 compared to $2.319 billion in the fourth quarter of the prior year. Worldwide COVID-19 testing-related sales were $8.368 billion in the full year of 2022 compared to $7.679 billion in the prior year.

The following tables summarize sales excluding COVID-19 testing-related sales and the change in reported and organic sales excluding COVID-19 testing-related sales in 2022 versus the prior year2:

% Change vs. 4Q21

Sales excl. COVID tests 4Q22

Reported excl. COVID tests

Organic excl. COVID tests

U.S.

Int’l

Total

U.S.

Int’l

Total

U.S.

Int’l

Total

Total 1

3,443

5,579

9,022

5.8

(5.4)

(1.4)

5.8

5.3

5.4

Diagnostics

919

1,317

2,236

16.8

(3.6)

3.8

16.8

8.0

11.2

% Change vs. 12M21

Sales excl. COVID tests 12M22

Reported excl. COVID tests

Organic excl. COVID tests

U.S.

Int’l

Total

U.S.

Int’l

Total

U.S.

Int’l

Total

Total

12,644

22,641

35,285

2.5

(1.8)

(0.3)

2.5

6.5

5.1

Diagnostics

3,148

5,068

8,216

11.4

(1.4)

3.1

11.4

7.1

8.6

Nutrition

($ in millions)

% Change vs. 4Q21

Sales 4Q22

Reported

Organic

U.S.

Int’l

Total

U.S.

Int’l

Total

U.S.

Int’l

Total

Total

795

1,022

1,817

(14.4)

(8.3)

(11.1)

(14.4)

1.4

(5.7)

Pediatric

454

428

882

(20.4)

(8.9)

(15.2)

(20.4)

(1.2)

(11.8)

Adult

341

594

935

(4.8)

(7.9)

(6.8)

(4.8)

3.4

0.5

% Change vs. 12M21

Sales 12M22

Reported

Organic

U.S.

Int’l

Total

U.S.

Int’l

Total

U.S.

Int’l

Total

Total

2,919

4,540

7,459

(17.9)

(4.2)

(10.1)

(17.9)

2.5

(6.2)

Pediatric

1,562

1,919

3,481

(28.7)

(8.9)

(19.0)

(28.7)

(3.9)

(16.6)

Adult

1,357

2,621

3,978

(0.5)

(0.4)

(0.4)

(0.5)

7.6

4.8

Worldwide Nutrition sales decreased 11.1 percent on a reported basis and 5.7 percent on an organic basis in the fourth quarter. Total worldwide Nutrition and Pediatric Nutrition sales were negatively impacted as a result of manufacturing disruptions during 2022 of certain infant formula products3 at Abbott’s Sturgis, Michigan, facility. The manufacturing facility has subsequently restarted production.

In Adult Nutrition, global sales decreased 6.8 percent on a reported basis and increased 0.5 percent on an organic basis in the fourth quarter, led by Ensure, Abbott’s market-leading complete and balanced nutrition brand.

Diagnostics

($ in millions)

% Change vs. 4Q21

Sales 4Q22

Reported

Organic

U.S.

Int’l

Total

U.S.

Int’l

Total

U.S.

Int’l

Total

Total

1,695

1,610

3,305

(29.0)

(22.8)

(26.1)

(29.0)

(12.5)

(21.3)

Core Laboratory

301

963

1,264

0.2

(8.1)

(6.3)

0.2

3.5

2.8

Molecular

62

118

180

(54.2)

(43.9)

(47.9)

(54.2)

(38.6)

(44.7)

Point of Care

88

43

131

(7.6)

7.0

(3.3)

(7.6)

14.4

(1.2)

Rapid Diagnostics

1,244

486

1,730

(33.0)

(38.2)

(34.5)

(33.0)

(28.3)

(31.6)

% Change vs. 12M21

Sales 12M22

Reported

Organic

U.S.

Int’l

Total

U.S.

Int’l

Total

U.S.

Int’l

Total

Total

8,646

7,938

16,584

21.3

(6.8)

6.0

21.3

1.3

10.4

Core Laboratory

1,137

3,751

4,888

(0.7)

(5.8)

(4.7)

(0.7)

2.7

1.9

Molecular

370

625

995

(34.6)

(27.4)

(30.3)

(34.6)

(22.6)

(27.4)

Point of Care

372

153

525

(3.2)

0.8

(2.1)

(3.2)

6.0

(0.6)

Rapid Diagnostics

6,767

3,409

10,176

34.4

(3.1)

19.0

34.4

5.4

22.5

As expected, Diagnostics sales in the fourth quarter were negatively impacted by year-over-year declines in COVID-19 testing-related sales. Worldwide COVID-19 testing-related sales were $1.069 billion in the fourth quarter of 2022 compared to $2.319 billion in the fourth quarter of the prior year.

The following tables summarize sales excluding COVID-19 testing-related sales and the change in reported and organic sales excluding COVID-19 testing-related sales in 2022 versus the prior year2:

% Change vs. 4Q21

Sales excl. COVID tests 4Q22

Reported excl. COVID tests

Organic excl. COVID tests

U.S.

Int’l

Total

U.S.

Int’l

Total

U.S.

Int’l

Total

Total

919

1,317

2,236

16.8

(3.6)

3.8

16.8

8.0

11.2

Core Laboratory

298

956

1,254

1.5

(5.3)

(3.8)

1.5

6.8

5.6

Molecular

45

98

143

(0.2)

(8.3)

(5.9)

(0.2)

(0.4)

(0.3)

Point of Care

88

43

131

(7.6)

7.0

(3.3)

(7.6)

14.4

(1.2)

Rapid Diagnostics

488

220

708

38.3

4.6

25.7

38.3

16.8

30.3

% Change vs. 12M21

Sales excl. COVID tests 12M22

Reported excl. COVID tests

Organic excl. COVID tests

U.S.

Int’l

Total

U.S.

Int’l

Total

U.S.

Int’l

Total

Total

3,148

5,068

8,216

11.4

(1.4)

3.1

11.4

7.1

8.6

Core Laboratory

1,121

3,705

4,826

1.3

(2.9)

(2.0)

1.3

5.8

4.8

Molecular

180

404

584

11.4

8.0

9.0

11.4

14.8

13.8

Point of Care

372

153

525

(3.2)

0.8

(2.1)

(3.2)

6.0

(0.6)

Rapid Diagnostics

1,475

806

2,281

25.6

1.3

15.8

25.6

9.4

19.1

Established Pharmaceuticals

($ in millions)

% Change vs. 4Q21

Sales 4Q22

Reported

Organic

U.S.

Int’l

Total

U.S.

Int’l

Total

U.S.

Int’l

Total

Total

1,216

1,216

n/a

1.0

1.0

n/a

7.9

7.9

Key Emerging Markets

902

902

n/a

3.9

3.9

n/a

10.3

10.3

Other

314

314

n/a

(6.5)

(6.5)

n/a

1.9

1.9

% Change vs. 12M21

Sales 12M22

Reported

Organic

U.S.

Int’l

Total

U.S.

Int’l

Total

U.S.

Int’l

Total

Total

4,912

4,912

n/a

4.1

4.1

n/a

10.6

10.6

Key Emerging Markets

3,728

3,728

n/a

5.4

5.4

n/a

11.8

11.8

Other

1,184

1,184

n/a

0.4

0.4

n/a

7.3

7.3

Established Pharmaceuticals sales increased 1.0 percent on a reported basis and 7.9 percent on an organic basis in the fourth quarter.

Key Emerging Markets include several emerging countries that represent the most attractive long-term growth opportunities for Abbott’s branded generics product portfolio. Sales in these geographies increased 3.9 percent on a reported basis and 10.3 percent on an organic basis, led by strong growth in several geographies including India, China, Brazil and Mexico, and across several therapeutic areas, including cardiometabolic, women’s health and central nervous system/pain management.

Medical Devices

($ in millions)

% Change vs. 4Q21

Sales 4Q22

Reported

Organic

U.S.

Int’l

Total

U.S.

Int’l

Total

U.S.

Int’l

Total

Total

1,726

2,024

3,750

12.2

(8.4)

12.2

4.1

7.4

Rhythm Management

254

260

514

5.2

(13.3)

(5.0)

5.2

(0.5)

2.1

Electrophysiology

242

245

487

22.7

(19.8)

(3.1)

22.7

(6.6)

4.9

Heart Failure

171

59

230

0.1

(13.9)

(3.9)

0.1

(4.5)

(1.2)

Vascular

214

391

605

(7.5)

(12.5)

(10.8)

(7.5)

(1.4)

(3.5)

Structural Heart

214

227

441

10.9

0.4

5.2

10.9

15.7

13.5

Neuromodulation

163

39

202

3.7

(3.1)

2.3

3.7

11.7

5.3

Diabetes Care

468

803

1,271

34.9

(2.5)

8.6

34.9

9.8

17.3

% Change vs. 12M21

Sales 12M22

Reported

Organic

U.S.

Int’l

Total

U.S.

Int’l

Total

U.S.

Int’l

Total

Total

6,566

8,121

14,687

10.9

(3.8)

2.2

10.9

6.2

8.1

Rhythm Management

1,029

1,090

2,119

1.1

(7.7)

(3.6)

1.1

1.9

1.5

Electrophysiology

909

1,018

1,927

17.0

(9.9)

1.1

17.0

0.7

7.3

Heart Failure

694

226

920

6.2

(4.0)

3.5

6.2

5.2

5.9

Vascular

864

1,619

2,483

(5.6)

(6.9)

(6.4)

(5.6)

1.5

(1.0)

Structural Heart

818

894

1,712

12.0

1.6

6.3

12.0

13.8

13.0

Neuromodulation

619

151

770

0.3

(8.1)

(1.4)

0.3

2.9

0.9

Diabetes Care

1,633

3,123

4,756

34.8

0.2

9.9

34.8

10.6

17.4

Worldwide Medical Devices sales were flat on a reported basis and increased 7.4 percent on an organic basis in the fourth quarter. Sales growth in the U.S. was led by strong double-digit growth in Electrophysiology, Structural Heart and Diabetes Care. Internationally, sales growth was negatively impacted by intermittent COVID-19 lockdown restrictions in China as well as supply constraints in certain areas, including Electrophysiology and Diabetes Care.

In Diabetes Care, FreeStyle Libre sales were approximately $1.1 billion in the quarter, including U.S. growth of more than 40 percent.

In 2022, Abbott continued to strengthen its Medical Devices portfolio with several recent pipeline advancements, including U.S. FDA approvals of:

Navitor, Abbott’s latest-generation transcatheter aortic valve implantation (TAVI) system, used for the treatment of severe aortic stenosis.
Eterna, Abbott’s rechargeable spinal cord stimulator used for treating chronic pain.
Aveir leadless pacemaker, used for treating patients with slow heart rhythms.
An expanded indication of use for CardioMEMS HF remote monitoring system, which detects early warning signs of worsening heart failure.
U.S. FDA clearance of the FreeStyle Libre 3 system, which provides continuous glucose readings and unsurpassed 14-day accuracy7 in the world’s smallest and thinnest7 wearable sensor.
ABBOTT’S EARNINGS-PER-SHARE GUIDANCE

Abbott projects full-year 2023 diluted earnings per share from continuing operations under GAAP of $3.05 to $3.25. Abbott forecasts specified items for the full-year 2023 of $1.25 per share primarily related to intangible amortization, restructuring and cost reduction initiatives and other net expenses. Excluding specified items, projected adjusted diluted earnings per share from continuing operations would be $4.30 to $4.50 for the full-year 2023.

ABBOTT DECLARES 396TH CONSECUTIVE QUARTERLY DIVIDEND

On Dec. 9, 2022, the board of directors of Abbott declared the company’s quarterly dividend of $0.51 per share. Abbott’s cash dividend is payable Feb. 15, 2023, to shareholders of record at the close of business on Jan. 13, 2023.

Abbott has increased its dividend payout for 51 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.

Carina receives ‘Safe to proceed’ letter for Phase 1/2a clinical trial of CNA3103

On January 24, 2023 Carina Biotech Pty Ltd ("Carina," "the Company"), a cell therapy immuno-oncology company developing CAR-T and other adoptive cell therapies for the treatment of solid cancers, reported that it has received the "safe to proceed" letter from the U.S. FDA for its Investigational New Drug (NDA) application to conduct a first-in-human Phase 1/2a clinical trial of CNA3103, its LGR5-targeted chimeric antigen receptor T cell (CAR-T) therapy candidate, in patients with advanced colorectal cancer (CRC) (Press release, Carina Biotech, JAN 24, 2023, View Source [SID1234629093]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Phase 1/2a clinical trial will enroll a total of 44 patients with metastatic disease failing prior lines of chemotherapy and who express LGR5 on their cancer cells. Twenty-four patients in the Phase 1 segment will be enrolled in select Australian centers. Following a BOIN (Bayesian Optimal Interval) design, ascending CAR-T cell doses will be administered to cohorts of three patients each, to assess the safety and tolerability of CNA3103, and to determine its optimal dose. The subsequent Phase 2 segment will enroll 20 patients at the optimal dose, in both Australia and the U.S., to characterize the activity of CNA3103, in terms of antitumor response, duration of response and time to disease progression.

"Our positive engagement with the FDA marks a major step forward for Carina and our continued efforts to develop CNA3103 as a potential treatment for the third most common cancer in the U.S. and worldwide, colorectal cancer," said Deborah Rathjen, Carina’s Chief Executive Officer. "The FDA’s letter provides the pathway for this clinical trial and further validates that a significant unmet need exists for more effective treatment options for colorectal cancer. Preparations, including site selection, are underway as we aim to commence enrolling patients during the first half of 2023."

"This interaction with the FDA corroborates our ability to gain the agency’s support for our proposed trial of CNA3103 in metastatic colorectal cancer patients," said José Iglesias, MD, Carina’s Chief Medical Officer. "Our approach is doubly innovative, in being one of the of emergent CAR-T treatment protocols in solid tumors and in utilizing a novel, and to our knowledge, unique CAR-T construct against LGR5 – an important cancer stem cell-associated antigen linked to the pathogenesis, dissemination, and treatment resistance of colorectal cancer."

About CNA3103

Carina’s proprietary CNA3103 CAR-T cell targets LGR5, a cancer stem cell marker that is highly expressed on advanced colorectal cancer and some other cancers. In colorectal cancer patients, LGR5 expression has been correlated with poor prognosis. Cancer stem cells are a small sub-population of cells within a tumor with the ability to self-renew, differentiate into the many cell types of a tumor, initiate new tumors, and resist chemotherapy and radiotherapy (leading to relapses). By targeting cancer stem cells, it is hoped that this therapy will reduce the tumor’s ability to generate new cancer cells, resulting in durable tumor suppression and preventing the relapses that are very common in patients with colorectal cancer. Carina’s pre-clinical studies of CNA3103 have shown promising results with complete tumor regression and no tumor recurrence following a single administration. CNA3103 has also demonstrated impressive tumor access and prolonged survival, enabling rejection of new tumors.

Unaudited Comparative Supplementary Sales Data and Condensed Consolidated Statement of Earnings for the fourth quarter and full year

On January 24, 2023 Johnson & Johnson reported its unaudited Comparative Supplementary Sales Data and Condensed Consolidated Statement of Earnings for the fourth quarter and full year (Press release, Johnson & Johnson, JAN 24, 2023, View Source [SID1234626657]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!